ROIV

Roivant Sciences Ltd. [ROIV] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ROIV Stock Summary

Top 10 Correlated Stocks

ROIV

In the News

ROIV Financial details

Company Rating
-
Market Cap
8.82B
Income
4.32B
Revenue
123.24M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
904
Optionable
No
Shortable
Yes
Earnings
26 Jun 2024
P/E
-7.56
Forward P/E
-
PEG
0.16
P/S
88.46
P/B
9.22
P/C
-
P/FCF
-10.72
Quick Ratio
5.51
Current Ratio
5.84
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
5.35
EPS next Y
-
EPS next Q
-
EPS this Y
25.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-18.6%
Revenue last 5Y
92.41%
Revenue Q/Q
0.11%
EPS Q/Q
-1692.5%
-
-
-
-
SMA20
-9.09%
SMA50
-9.09%
SMA100
-16.67%
Inst Own
-
Inst Trans
-
ROA
-56%
ROE
-95%
ROC
-0.29%
Gross Margin
85%
Oper. Margin
-499%
Profit Margin
-1121%
Payout
-1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.01-13.24
52W High
-23.12%
52W Low
+42.79%
RSI
39
Rel Volume
0.84
Avg Volume
7.44M
Volume
6.29M
Perf Week
-4.26%
Perf Month
-6.41%
Perf Quarter
-15.8%
Perf Half Y
-13.39%
-
-
-
-
Beta
1.342
-
-
Volatility
0.2%, 0.28%
Prev Close
-0.84%
Price
9.995
Change
1.99%

Something similar

Top by Market Cap
CMC.DE
VTSAX
1YD.DE
META
VFINX
Same Sector
SUS.ST
0Y6X.L
PLNHF
DXR
LOTUSEYE.NS
Top Correlated Stocks
GENC
IMTX
Similar Market Cap
HHHSX
0HIN.L
ADSL.NS
002061.SZ
PAGERO.ST

Company Profile

Healthcare Biotechnology
  • Volume Average 7.44M
  • Market Capitalization 8.82B
  • Employee 904
  • CEO Mr. Matthew Gline
  • Headquarters London,GB
  • IPO Date 2020-12-08
  • Website https://roivant.com

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.